Plegridy two year data confirms safety and efficacy in MS

[MSUK]

Plegridy two year data confirms safety and efficacy in MS patients

Biogen Idec today announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of Plegridy™ (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.... Read More - http://www.ms-uk.org/plegridy